FDA warned Glow Nest Beauty that its website sells unapproved, misbranded injectable botulinum toxin Rentox 200U.
What happened
FDA reviewed www.glownestbeauty.com and found it offering botulinum toxin type A as “Rentox 200U – Botulinum Toxin Type A” and “Rentox 200U” for sale to U.S. consumers. FDA said the product is an unapproved new drug and is misbranded because it is a prescription drug offered without a prescription and without adequate directions for lay use.
What FDA found
The website offers “Rentox 200U” botulinum toxin type A as a new drug without an FDA-approved application.
FD&C Act sections 301(d) and 505(a) [21 U.S.C. §§ 331(d), 355(a)]The product’s labeling lacks adequate directions for use because a layperson cannot safely use this prescription injectable.
FD&C Act section 502(f)(1) [21 U.S.C. § 352(f)(1)]The website offers a prescription drug without requiring a prescription, misbranding it while held for sale.
FD&C Act sections 503(b)(1) and 301(k) [21 U.S.C. §§ 353(b)(1), 331(k)]By offering the unapproved and misbranded drug to U.S. consumers, the website causes it to be introduced into interstate commerce.
FD&C Act section 301(a) [21 U.S.C. § 331(a)]
What FDA wants
FDA asks Glow Nest Beauty to stop offering the unapproved and misbranded drugs to U.S. consumers and to review its websites, labels, and promotional materials. The company must respond in writing within 15 working days with corrective steps, documentation, or its reasoning and supporting information.
Who should pay attention
- online sellers of injectable cosmetic drugs
- consumers buying botulinum toxin online
- distributors and suppliers of unapproved botulinum toxin products
This is a summary. Read the original letter on fda.gov.